Impact of alternative diagnostic labels for melanoma in situ on management choices and psychological outcomes: protocol for an online randomised study DOI Creative Commons

Zhongfei Wu,

Brooke Nickel, Farzaneh Boroumand

et al.

BMJ Open, Journal Year: 2024, Volume and Issue: 14(12), P. e089558 - e089558

Published: Dec. 1, 2024

A diagnosis of melanoma in situ presents negligible risk to a person's lifespan or physical well-being, but existing terminology makes it difficult for patients distinguish these from higher invasive melanomas. This study aims explore whether using an alternative label may influence patients' management choices and anxiety levels. is between-subjects randomised online experiment, hypothetical scenarios. Following consent, eligible participants will be 1:1:1 three labels: 'melanoma situ' (control), 'low-risk melanocytic neoplasm' (intervention 1) neoplasm, 2). The required sample size 1668 people. co-primary outcomes are (1) choice between no further surgery ensure clear histological margins greater than 5 mm (2) patient-initiated clinical follow-up when needed (patient-led surveillance) regular routinely scheduled (clinician-led surveillance). Secondary include anxiety, perceived dying (after choice). We make pairwise comparisons across the diagnostic groups regression models (univariable multivariable). has been registered with Australian New Zealand Clinical Trials Registry (ACTRN12624000740594). Ethics approval received University Sydney Human Research Committee (2024/HE000019). results published peer-reviewed medical journal, plain language summary findings shared on Wiser Healthcare publication page (https://www.wiserhealthcare.org.au/category/publications/). (ID 386943).

Language: Английский

Local recurrence of non‐lentigo maligna melanoma in situ and safety excision margins: A systematic review DOI
Clio Dessinioti,

Aggeliki Befon,

Alexander J. Stratigos

et al.

JDDG Journal der Deutschen Dermatologischen Gesellschaft, Journal Year: 2025, Volume and Issue: unknown

Published: April 15, 2025

Summary The strength of evidence supporting a 2‐step wide local excision (WLE) with 5 mm safety margins for melanoma in situ non‐lentigo maligna (non‐LM) type, compared narrower margins, is unclear. This review aims to compare the frequency recurrence (LR) different after complete surgical (R0) non‐LM MIS. We performed systematic literature search PubMed, Scopus, and Cochrane Library up March 17, 2024. PRISMA checklist was used. Of 3,047 articles retrieved, seven retrospective studies were included, enrolling total 1,526 MIS cases excised clear WLE (6 studies) or Mohs surgery (1 study). Most located on trunk/extremities (68%–100%). Narrower used four studies, ranging from no 4 mm, there only one LR. Standard wider remaining three reporting two median follow‐up ranged 48 months 6.6 years. overall certainty quality very low. These findings our highlight that current guidelines recommending re‐excision initial lack strong support this practice.

Language: Английский

Citations

0
Recurrence Rate of Melanoma In Situ Excised With a 5-mm Excisional Margin DOI
John A. Zitelli

JAMA Dermatology, Journal Year: 2024, Volume and Issue: 160(8), P. 803 - 803

Published: Aug. 1, 2024

Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Journals Network Open Cardiology Health Forum Internal Medicine Neurology Oncology Ophthalmology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy Accessibility Statement 2024 American Medical Association. All Rights Reserved Search Archive Input Term Sign In Individual inCreate an Account Access through institution Purchase Options: Buy this article Rent Subscribe the journal

Language: Английский

Citations

0
Impact of alternative diagnostic labels for melanoma in situ on management choices and psychological outcomes: protocol for an online randomised study DOI Creative Commons

Zhongfei Wu,

Brooke Nickel, Farzaneh Boroumand

et al.

BMJ Open, Journal Year: 2024, Volume and Issue: 14(12), P. e089558 - e089558

Published: Dec. 1, 2024

A diagnosis of melanoma in situ presents negligible risk to a person's lifespan or physical well-being, but existing terminology makes it difficult for patients distinguish these from higher invasive melanomas. This study aims explore whether using an alternative label may influence patients' management choices and anxiety levels. is between-subjects randomised online experiment, hypothetical scenarios. Following consent, eligible participants will be 1:1:1 three labels: 'melanoma situ' (control), 'low-risk melanocytic neoplasm' (intervention 1) neoplasm, 2). The required sample size 1668 people. co-primary outcomes are (1) choice between no further surgery ensure clear histological margins greater than 5 mm (2) patient-initiated clinical follow-up when needed (patient-led surveillance) regular routinely scheduled (clinician-led surveillance). Secondary include anxiety, perceived dying (after choice). We make pairwise comparisons across the diagnostic groups regression models (univariable multivariable). has been registered with Australian New Zealand Clinical Trials Registry (ACTRN12624000740594). Ethics approval received University Sydney Human Research Committee (2024/HE000019). results published peer-reviewed medical journal, plain language summary findings shared on Wiser Healthcare publication page (https://www.wiserhealthcare.org.au/category/publications/). (ID 386943).

Language: Английский

Citations

0